Nuclear Science and Techniques

《核技术》(英文版) ISSN 1001-8042 CN 31-1559/TL     2019 Impact factor 1.556

Nuclear Science and Techniques ›› 2012, Vol. 23 ›› Issue (3): 169-175 doi: 10.13538/j.1001-8042/nst.23.169-175

• RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICIN • Previous Articles     Next Articles

Clinical value of 18F-FDG PET/CT in evaluation of hepatic vein,inferior vena cava and right atrium tumor thrombi in hepatocellular carcinoma:Initial results

SUN Long ZHAO Long LUO Zuoming JIANG Maoqing WU Hua*   

  1. Minnan PET Center and Department of Nulear Medicine,No.1 Hospital Affiliated to Xiamen University,Xiamen 361003,China
SUN Long, ZHAO Long, LUO Zuoming, JIANG Maoqing, WU Hua. Clinical value of 18F-FDG PET/CT in evaluation of hepatic vein,inferior vena cava and right atrium tumor thrombi in hepatocellular carcinoma:Initial results.Nuclear Science and Techniques, 2012, 23(3): 169-175     doi: 10.13538/j.1001-8042/nst.23.169-175

Abstract:

In this paper,eleven consecutive hepatocellular carcinoma(HCC) patients with an embolus in the hepatic vein(HV),inferior vena cava(IVC)and right atrium(RA) were studied with 18F-FDG PET/CT and contrast enhanced CT.When correlated with final diagnosis,18F-FDG PET/CT and contrast enhanced CT was positive in 11 patients(100%),7 patients(63.6%),respectively.The accuracy of PET/CT and contrast-enhanced CT were 100%,63.6%.Three cases with secondary blood thrombi in the distant IVC,which were confirmed by PET/CT,cannot be identified by contrast enhanced CT.The average survival was 3 months(range,1-12mo).The 12 months survival rate was 9.1%.Our results suggest that highly metabolic tumor thrombus in the HV,IVC and RA may be depicted on 18F-FDG PET/CT in HCC patients.It may discriminate between malignant and secondary benign blood thrombi.

Key words: Hepatocellular carcinoma, Contrast-enhanced CT, Positron emission tomography/computed tomography, Hepatic vein tumor thrombus, Right atrium, Tumor thrombus